Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2018-A00146-49 | Registry Identifier | ID RCB |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Severe mental illness is accompanied by cognitive fluctuations that can alter decision-making skills and lead to coerced care. Taking into account, on the one hand, the health, social and economic impact of forced hospitalization, on the other hand the importance of self-determination, the reinforcement of the power to act in the evolution of these disorders, new strategies to better reflect the views of people have been developed.
Among these, the drafting of Advanced Directives in Psychiatric (ADP), allows people with mental disorders to write while their decision-making skills are restored care instructions in case of decompensation.
It is a tool of "advanced therapeutic education" and early prevention of relapses.
It is hypothesized that the implementation of drafting accompanied by advance directives to people with severe psychiatric disorders decreases in the short term the number of forced hospitalization care pathway of these people, compared to the subjects having not benefited from this device.
This research will take the form of a randomized controlled trial on 3 sites. The "quantitative" evaluation component of results and processes will be completed with a qualitative anthropological and socio-political evaluation component documenting the trajectories of individuals and the implementation of the program, as well as a "participatory research" component aimed at a dialogue between users, researchers and professionals.
The patient who is a beneficiary of the "Advanced Directives in Psychiatric" program will be encouraged to complete the " Advanced Directives in Psychiatric" document and will receive support in drafting them. The non-beneficiary patient of the program will follow up with his psychiatrist unchanged.
The experimental design of the quantitative component is based on an experimental, randomized, prospective, controlled, parallel study, comparing two groups of subjects with severe psychiatric disorders.
This research will assess the effectiveness, efficiency and impact of the " Advanced Directives in Psychiatric" program compared to conventional psychiatric care alone.
Ultimately, the objective of describing the effects of the program on health organizations and on the representations and practices of professionals, caregivers and users is at the service of a better understanding of the conditions of possibility of the generalization of this experimentation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| beneficiary of the advance directive program | Experimental |
| |
| beneficiary of standard Support | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Psychiatric Advanced Directive | Behavioral | The patient completes a questionnaire to express in advance his wishes regarding his future care in psychiatry. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Rate of patients with compulsory admission | Evaluation of the hospitalization rate by comparing the two groups | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Evaluation of patient recovery rates | The rate is assessed by the Recovery Assessment Scale (RAS) | 12 months |
| Evaluation of the empowerment rate | The rate is assessed by the Empowerment Scale (ES) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jean-Olivier ARNAUD, Director | Assistance Publique Hôpitaux de Marseille | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille | Marseille | 13354 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40050829 | Derived | Desvignes S, Boucekine M, Loubiere S, Leclerc L, Auquier P, Tinland A. Validation of a French version of the empowerment scale for mental health service users. BMC Psychiatry. 2025 Mar 6;25(1):207. doi: 10.1186/s12888-025-06554-4. | |
| 35662314 | Derived | Tinland A, Loubiere S, Mougeot F, Jouet E, Pontier M, Baumstarck K, Loundou A, Franck N, Lancon C, Auquier P; DAiP Group. Effect of Psychiatric Advance Directives Facilitated by Peer Workers on Compulsory Admission Among People With Mental Illness: A Randomized Clinical Trial. JAMA Psychiatry. 2022 Aug 1;79(8):752-759. doi: 10.1001/jamapsychiatry.2022.1627. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard care | Behavioral | standardized maintenance with the patient |
|
| 12 months |
| Measuring the health-related quality of life of patients | Health-related quality of life is measured using a specific scale: the S-QOL. It is a self-reported instrument of 41 items that assesses the quality of life in patients with schizophrenia | 12 months |
| Measuring mental health symptoms of patients | Mental health symptoms are measured by Modified Colorado Symptom Index (MCSI) | 12 months |
| Evaluation of the therapeutic alliance between the patient and his psychiatrist | The therapeutic alliance between the patient and his psychiatrist is assessed by the 4-Point Alliance Self Report (4-PAS) questionnaire | 12 months |
| Measuring Disease Awareness | Disease Awareness is assessed by the évaluée par l'échelle SUMD (Scale to Assess Unawareness in Mental Disorder | 12 months |
| Evaluation of the severity of the psychiatric disorder by the psychiatrist | The severity of the psychiatric disorder is assessed by the Clinical Global Impression (ICG) scale | 12 months |
| Medico-economic analysis (cost-utility) | Number of inpatient | 12 months |
| Medico-economic analysis (cost-utility) | Number of emergency department visits | 12 months |
| Medico-economic analysis (cost-utility) | Number of outpatient visits | 12 months |
| Medico-economic analysis (cost-utility) | Loss of productivity | 12 months |
| 31881954 | Derived | Tinland A, Leclerc L, Loubiere S, Mougeot F, Greacen T, Pontier M, Franck N, Lancon C, Boucekine M, Auquier P. Psychiatric advance directives for people living with schizophrenia, bipolar I disorders, or schizoaffective disorders: Study protocol for a randomized controlled trial - DAiP study. BMC Psychiatry. 2019 Dec 27;19(1):422. doi: 10.1186/s12888-019-2416-9. |
| ID | Term |
|---|---|
| D012559 | Schizophrenia |
| ID | Term |
|---|---|
| D019967 | Schizophrenia Spectrum and Other Psychotic Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D059039 | Standard of Care |
| ID | Term |
|---|---|
| D019984 | Quality Indicators, Health Care |
| D011787 | Quality of Health Care |
| D006298 | Health Services Administration |
| D017530 | Health Care Quality, Access, and Evaluation |
Not provided
Not provided